Two Sigma Investments
CGTX icon

Two Sigma Investments’s Cognition Therapeutics CGTX Stock Holding History

Two Sigma Investments’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.6K Sell
19,229
-28,500
-60% -$33.2K ﹤0.01% 4520
2025
Q4 		$64.4K Sell
47,729
-49,262
-51% -$80K ﹤0.01% 3906
2025
Q3 		$131K Buy
96,991
+1,792
+2% +$2.44K ﹤0.01% 3435
2025
Q2 		$29.5K Buy
95,199
+12,655
+15% +$4.27K ﹤0.01% 3100
2025
Q1 		$34.7K Buy
82,544
+28,853
+54% +$17K ﹤0.01% 3074
2024
Q4 		$37.7K Buy
53,691
+42,321
+372% +$20.9K ﹤0.01% 3066
2024
Q3 		$5.33K Buy
+11,370
New +$11.7K ﹤0.01% 3063
2023
Q2 		– Sell
-28,236
Closed -$55.9K – 3039
2023
Q1 		$55.9K Sell
28,236
-18,384
-39% -$35K ﹤0.01% 2738
2022
Q4 		$97.9K Buy
46,620
+22,213
+91% +$44.9K ﹤0.01% 2511
2022
Q3 		$46K Buy
+24,407
New +$50.8K ﹤0.01% 2323
2022
Q2 		– Sell
-42,102
Closed -$116K – 2561
2022
Q1 		$116K Sell
42,102
-41,296
-50% -$159K ﹤0.01% 2416
2021
Q4 		$527K Buy
+83,398
New +$813K ﹤0.01% 3205

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Two Sigma Investments's CGTX Position: Q1 2026 in Review

Two Sigma Investments reduced its Cognition Therapeutics (CGTX) stake by 60% in Q1 2026, selling an estimated $33.2K and leaving 19,229 shares worth $14.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4520.

Two Sigma Investments first reported a position in CGTX in Q4 2021 and has held it in 12 quarters since. The position peaked at $527K in Q4 2021. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Two Sigma Investments held 19,229 shares of Cognition Therapeutics worth $14.6K as of Q1 2026.
  • Two Sigma Investments sold 28,500 Cognition Therapeutics shares in Q1 2026, an estimated $33.2K.
  • Cognition Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #4520 holding.
  • Two Sigma Investments first reported a position in Cognition Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • Two Sigma Investments's Cognition Therapeutics position peaked at $527K in Q4 2021.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.